PGT develops and commercializes proprietary vaccine technologies that address unmet needs in both the veterinary and human health fields with a focus on infectious disease. We produce either “first-in-class” vaccines and adjuvant solutions or replacement products where legacy offerings are problematic.
PGT’s business strategy is based on acquiring exclusive rights to novel and potentially disruptive vaccine and adjuvant technologies that require commercial development, distribution and intellectual property protection. PGT assumes the role of business development partner and undertakes the steps necessary to commercialize new technologies.
PGT has the exclusive global licenses for innovative and IP protected technology platforms to produce vaccines and adjuvants that are effective and very low costs to produce and to administer.